Methotrexate in psoriatic arthritis

Clinical and Experimental Rheumatology

Volumn 20, Issue 6 SUPPL. 28, 2002, Pages

  Cutolo, Maurizio ^a   Seriolo, B ^a   Pizzorni, C ^a   Craviotto, C ^a   Sulli, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Folic acid; Methotrexate; Psoriasis; Psoriatic arthritis

Indexed keywords

AMINOPTERIN; ANTIRHEUMATIC AGENT; AUROTHIOMALATE; CAFFEINE; CYCLOSPORIN A; FOLIC ACID; FOLIC ACID DERIVATIVE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LUNG FIBROSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; STOMATITIS; PRACTICE GUIDELINE; REVIEW; SAFETY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; METHOTREXATE; PRACTICE GUIDELINES; SAFETY;

EID: 1842844044     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. SEEGER DR, COSALICH DDB, SMITH JM, HULTQUIST ME: Analogs of pteroylglutamic acid. II. 4-aminoderivatives. J Am Chem Soc 1949; 71: 1297-301.
2. GUBNER R, AUGUST S, GINSBERG V: Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176-82.
3. WEINSTAEIN GD, FROST P: Methotrexate for psoriasis: A new therapaeutic schedule. Arch Dermatol 1971; 103: 33-6.
4. CRONSTEIN BN: The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997; 23: 739-55.
5. HU SHK, MITCHO YL, ORONSKY AL, KEWAR SS: Studies on the effect of methotrexate on macrophage function. J Rheumatol 1988; 15: 206-9.
6. JOHNSON WJ, DI MARTINO MJ, MEUNIER PC, MURIHEAD KA, HANNA N: Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjiuvant induced arthritis. J Rheumatol 1988; 15: 745-9.
7. CRONSTEIN BN, EBERLE MA, GRUBER HE, LEVIN RI: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991; 88: 2441-5.
8. CUTOLO M, STRAUB RH: Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001; 60: 729-35.
9. LINK AA, KINO T, WORTH JA et al.: Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol 2000; 164: 436-42.
10. SAJJADI FG, TAKABAYASHI K, FOSTER AC, DOMINGO RC, FIRESTEIN GS: Inhibition of TNF-alpha expression by adenosine: Role of A3 adenosine receptors. J Immunol 1996; 156: 3435-42.
11. CUTOLO M, BISSO A, SULLI A et al.: Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from rheumatoid arthritis patients. J Rheumatol 2000: 27: 2551-7.
12. CUELLAR ML, ESPINOZA LR: Methotrexate in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am 1997; 23: 797-809.
13. BLACK RL, O'BRIEN WM, VAN SCOTT EJ et al.: Methotrexate therapy in psoriatic arthritis. JAMA 1964; 189: 743-7.
14. KRAGBALLE K, ZACHARIAE E, ZACHARIAE H: Methotrexate in psoriatic arthritis: A retrospective study. Acta Derm Venereol 1983; 63: 165-7.
15. WILLKENS RE, WILLIAMS HJ, WARD JR et al.: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984; 27: 376-81.
16. ESPINOZA LR. ZAKRAOUI L, ESPINOZA CG et al.: Clinical response and side effects to MTX therapy. J Rheumatol 1992; 12: 872-7.
17. ESPINOZA LR, ZAKRAOUI L, ESPINOZA CG et al.: Psoriatic arthritis: Clinical response and side effects to methotrexate therapy. J Rheumatol 1993; 20: 1804-5.
18. SINGH YN, VERMA KK, KUMAR A, MALAVIYA AN: Methotrexate in psoriatic arthritis. J Assoc Physicians India 1994; 23: 860-2.
19. ABU-SHAKRA M, GLADMAN DD, THORNE JC, LONG J, GOUGH J, FAREWELL VT: Long-term methotrexate therapy in psoriatic arthritis: Clinical and radiological outcome. Rheumatology 1995; 22: 241-5.
20. SPADARO A, RICCIERI V, SILI-SCAVALLI A, SENSI E TACCARI E, ZOPPINI A: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study. Clin Exp Rheumatol 1995; 13: 589-93.
21. ESPINOZA LR, CUELLAR ML: Psoriatic arthritis: Management. In KLIPPEL JH and DIEPPE PA (Eds.): Rheumatology, Mosby 1998; 6: 23-1,23-6.
22. OGILVIE AL, ANTONI C, DECHANT C et al.: Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 200 1; 144: 587-9.
23. WOLLINA U, STANDER K, BARTA U: Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis - Short- and long-term toxicity in 104 patients. Clin Rheumatol 2001; 406-10.
24. BELZUNEGUI J, INTXAUSTI JJ, DE DIOS JR et al.: Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol 2001: 727-30.
25. GOMEZ-VAQUERO C, RODRIGUEZ-MORENO J, ROS S, MARCOS R, FITER J, ROIG-ESCOFET D: Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment. Br J Rheumatol 1996; 36: 564-7.
26. LEEB BF, WITZMANN G, OGRIS E et al.: Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995; 13: 459-63.
27. KREMER JM, ALARCON GS, LIGHTFOOT RW JR et al.: Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-28.
28. NAKASHIMA-MATSUSHITA N, HOMMA T, YU S: Selective expression of folate receptor and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999; 8: 1609-16.
29. BRESSOLLE F, KINOWSKI JM, MOREL J, POULY B, SANY J. COMBRE B: Folic acid alters methotrexate availability in patients with rheumatoid arthritis. J Rheumatol 2000; 27: 2110-4.
30. GRIFFITH SM, FISHER J, CLARKE S: Do patients with RA established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology 2000; 39: 1102-9.
31. SHIROKY JB: The use of folates concomitantly with low-dose pulse methotrexate. Rheum Dis Clin North Am 1997; 23: 969-80.
32. JOBANPUTRA P, HUNTER M, CLARK D: An audit of methotrexate and folic acid for rheumatoid arthritis. Experience from a teaching centre. Br J Rheumatol 1995; 34: 971-9.
33. MORGAN SL, BAGGOT JE. VAUGHN WH: Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 833-42.
34. VAN EDE AE, LAAN RFGM, BLOM HJ, DE ABREU RAD, VAN DE PUTTE LBA: Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998; 27: 277-92.
35. MONTESINOS MC, YAP JS, DESAI A, POSADAS I, McCRARY C, CRONSTEIN B: Reversal of the antiinflammatory effects of methotrexate by nonselective adenosine receptor antagonists theophilline and caffeine. Arthritis Rheum 2000 43: 656-63.
36. SALVARANI C, MACCHIONI PL, CUTOLO M et al.: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28: 2274-82.
37. VAN EDE AE, LAAN RFJM, ROOD MJ et al.: Efficacy of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2001; 44: 1515-24.